tirzepatide microdosing reddit chart: Guide to benefits, dosage and safety Microdosing GLP-1 Medications: Risks and

doi: 10.2337/db15-1615 77 PllnenPMLempainenJLaineAPToppariJVeijolaRIlonenJet al

1 In the REIMAGINE 2 trial, the most commonly reported AEs were GI-related, occurring in 405/603 (67.2%) participants in the CagriSema 2.4 mg/2.4 mg group, 326/605 (53.9%) participants in the semaglutide 2.4 mg group, 60/152 (39.5%) participants in the cagrilintide 2.4 mg group, 329/594 (55.4%) participants in the CagriSema 1 mg/1 mg group, 288/608 (47.4%) participants in the semaglutide 1 mg group, and 42/149 (28.2%) participants in the placebo group

Schedule prompt medical evaluation (within 24-48 hours) for: Gradually worsening shortness of breath over days to weeks Dyspnea with exertion that is new or significantly worse than baseline Breathing difficulty accompanied by persistent cough or fever Leg swelling, weight gain, or orthopnea (difficulty breathing when lying flat) Respiratory symptoms associated with severe ongoing nausea, vomiting, or inability to maintain hydration Patients should not discontinue GLP-1 medications without medical guidance (except in cases of suspected severe allergic reactions), but should contact their healthcare provider promptly to discuss respiratory symptoms

Novel insight into streptozotocin-induced diabetic rats from the protein misfolding perspective